Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.

HOME
>
論文・技術情報
>
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.

Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.

アブストラクト	OBJECTIVES: This report describes the baseline clinical profiles and management of DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) trial participants and how these compare with those in other contemporary heart failure with preserved ejection fraction trials. BACKGROUND: The DELIVER trial was designed to evaluate the effects of the sodium-glucose cotransporter-2 inhibitor dapagliflozin on cardiovascular death, heart failure (HF) hospitalization, or urgent HF visits in patients with HF with mildly reduced and preserved left ventricular ejection fraction (LVEF). METHODS: Adults with symptomatic HF and LVEF >40%, with or without type 2 diabetes mellitus, elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and evidence of structural heart disease were randomized to dapagliflozin 10 mg once daily or matching placebo. RESULTS: A total of 6,263 patients were randomized (mean age: 72 +/- 10 years; 44% women; 45% type 2 diabetes mellitus; 45% with body mass index >/=30 kg/m(2); and 57% with history of atrial fibrillation or flutter). Most participants had New York Heart Association functional class II symptoms (75%). Baseline mean LVEF was 54.2 +/- 8.8% and median NT-proBNP of 1,399 pg/mL (IQR: 962 to 2,210 pg/mL) for patients in atrial fibrillation/flutter compared with 716 pg/mL (IQR: 469 to 1,281 pg/mL) in those who were not. Patients in both hospitalized and ambulatory settings were enrolled, including 10% enrolled in-hospital or within 30 days of a hospitalization for HF. Eighteen percent of participants had HF with improved LVEF. CONCLUSIONS: DELIVER is the largest and broadest clinical trial of this population to date and enrolled high-risk, well-treated patients with HF with mildly reduced and preserved LVEF. (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure [NCT03619213]).
ジャーナル名	JACC. Heart failure
投稿日	2022/3/5
投稿者	Solomon, Scott D; Vaduganathan, Muthiah; Claggett, Brian L; de Boer, Rudolf A; DeMets, David; Hernandez, Adrian F; Inzucchi, Silvio E; Kosiborod, Mikhail N; Lam, Carolyn S P; Martinez, Felipe; Shah, Sanjiv J; Belohlavek, Jan; Chiang, Chern-En; Willem Borleffs, C Jan; Comin-Colet, Josep; Dobreanu, Dan; Drozdz, Jaroslaw; Fang, James C; Alcocer Gamba, Marco Antonio; Al Habeeb, Waleed; Han, Yaling; Cabrera Honorio, Jose Walter; Janssens, Stefan P; Katova, Tsvetana; Kitakaze, Masafumi; Merkely, Bela; O'Meara, Eileen; Kerr Saraiva, Jose Francisco; Tereschenko, Sergey N; Thierer, Jorge; Vardeny, Orly; Verma, Subodh; Vinh, Pham Nguyen; Wilderang, Ulrica; Zaozerska, Natalia; Lindholm, Daniel; Petersson, Magnus; McMurray, John J V
組織名	Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School,;Boston, Massachusetts, USA. Electronic address: ssolomon@bwh.harvard.edu.;Boston, Massachusetts, USA.;University of Groningen, Groningen, the Netherlands.;University of Wisconsin, Madison, Wisconsin, USA.;Duke University Medical Center, Durham, North Carolina, USA.;Yale School of Medicine, New Haven, Connecticut, USA.;Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.;University of Groningen, Groningen, the Netherlands; National Heart Centre;Singapore & Duke-National University of Singapore, Singapore.;University of Cordoba, Cordoba, Argentina.;Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.;General University Hospital, Charles University, Prague, Czech Republic.;General Clinical Research Center and Division of Cardiology, Taipei Veterans;General Hospital and National Yang Ming Chiao Tung University, Taipei, Taiwan.;Haga Teaching Hospital, The Hague, Netherlands.;Cardiology Department, Bellvitge University Hospital, Bio-Heart (IDIBELL),;University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain.;University of Medicine, Pharmacy, Science and Technology "G.E.Palade," Targu;Mures, Romania.;Department Cardiology, Medical University Lodz, Lodz, Poland.;University of Utah Medical Center, Salt Lake City, Utah, USA.;Centro de Estudios Clinicos de Queretaro (CECLIQ), Queretaro, Mexico.;Cardiac Sciences Department, King Saud University, Riyadh, Saudi Arabia.;Cardiovascular Research Institute, Department of Cardiology, General Hospital of;Northern Theater Command, Shenyang, China.;Clinica Vesalio, San Borja, Peru.;Cardiac Intensive Care, Department of Cardiovascular Diseases, University;Hospitals Leuven, Leuven, Belgium.;Department of Noninvasive Cardiology, National Cardiology Hospital, Sofia,;Bulgaria.;Kinshukai Hanwa Daini Senboku Hospital, Osaka, JapanHeart and Vascular Center.;Semmelweis University, Budapest, Hungary.;Institut de Cardiologie de Montreal, Universite de Montreal, Montreal, Quebec,;Canada.;Cardiovascular Division, Instituto de Pesquisa Clinica de Campinas, Campinas SP,;Brazil.;Department of Myocardial Disease and Heart Failure, National Medical Research;Center of Cardiology, Moscow, Russia.;Jefe de Unidad de Insuficiencia Cardiaca, Centro de Educacion Medica e;Investigaciones Clinicas Norberto Quirno (CEMIC), Argentina.;Minneapolis VA Center for Care Delivery and Outcomes Research, University of;Minnesota, Minneapolis, Minnesota, USA.;Division of Cardiac Surgery, St Michael's Hospital, University of Toronto,;Toronto, Canada.;Cardiovascular Center, Tam Anh hospital, Tan Tao University, Vietnam.;Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals;R&D, AstraZeneca, Gothenburg, Sweden.;University of Glasgow, Glasgow, Scotland, UK.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/35241246/